Inovio announces positive HPV vaccine PhIIb results; NanoBio's genital herpes candidate shows efficacy in animal model;

> Inovio Pharmaceuticals ($INO) reported positive Phase IIb studies of its VGX-3100, announcing that in women with high grade cervical neoplasia, the immunotherapy produced killer T cells that were able to clear lesions and the HPV virus itself. Release

> Ann Arbor, MI-based NanoBio announced that its adjuvanted genital herpes vaccine candidate showed efficacy in guinea pigs. Statement

> IDK Biologika opened its first U.S. vaccine manufacturing plant in Rockville, MD. Announcement

> Abivax named Dr. Jean-Marc Steens its chief medical officer. Release

Suggested Articles

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.